Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
CRISPR
Sort By
Newest First
1 / 3
CRISPR
The Groundbreaking Potential of CRISPR Gene Editing
Olivia Newton-John Cancer Research Institute
PAO-10-24-RTM-09
Nov 05, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-10-24-CL-01
Sep 30, 2024
dbDNA
Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA
Jill Makin
Touchlight
PAO-08-24-CL-01
Aug 19, 2024
Cell Therapy
Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support
Sarah Meeks, Ph.D.
MaxCyte
PAO-09-23-CL-09
Sep 28, 2023
Lipid Nanoparticle Development
Lipid Technology for Delivery of Gene-Editing Therapies
Stephen Burgess, Ph.D.
Croda Pharma
PAO-11-022-CL-18
Jan 17, 2023
Gladstone Institutes
CRISPR Research Innovation
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Gladstone Institutes
PR-M08-22-05
Aug 25, 2022
SNIPR BIOME
CRISPR Clinical Trial
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
SNIPR BIOME
PR-M04-22-11
Apr 20, 2022
U.S. Food & Drug Administration
Regulatory
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
U.S. Food & Drug Administration
PR-M03-22-03
Mar 07, 2022
Gene Therapy
Beyond 2020: Looking into the Crystal Ball for Gene Therapy
Ratish Krishnan
MilliporeSigma
PAO-01-21-CL-03
Feb 01, 2021
CRISPR RNPs
CRISPR RNPs and the Future of Cell and Gene Therapy
Thomas Lynch, Ph.D.
Aldevron
PAP-Q3-20-CL-002
Sep 29, 2020
Synthego
Synthego Raises $100 Million to Accelerate CRISPR Platform Scale-up in Response to Growing Demand
Synthego
PR-M08-20-NI-43
Aug 26, 2020
Vertex
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
Vertex
PR-M06-20-NI-017
Jun 12, 2020
CRISPR-Cas9
How Close Is CRISPR to Eradicating Disease and Correcting Genetic Defects?
KshitiJ (TJ) Ladage
Nice Insight
PAP-Q1-20-NI-003
Mar 19, 2020
CRISPR-Cas9
CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway
Lydia Michaut
BioAgilytix
PAP-Q4-19-CL-011
Dec 06, 2019
Vertex
Cell and Gene Therapy
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Vertex
PR-M11-19-NI-023
Nov 20, 2019
CRISPR
Startup Navega Therapeutics Aims to Develop a CRISPR Treatment for Pain
Emilie Branch
Pharma's Almanac
PAO-M09-19-NI-008
Sep 04, 2019
Virus
New Insights into Virus Evasion Tactics
Pharma's Almanac
PAO-M00-19-NI-003
Sep 04, 2019
CRISPR
Scientists Edit Stem Cell–Derived Neurons Using CRISPR
Pharma's Almanac
PAO-M08-19-NI-039
Aug 27, 2019
CRISPR-Cas
Editing Many Sites at Once With CRISPR-Cas
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-032
Aug 27, 2019
The Wyss Institute for Biologically Inspired Engineering at Harvard University
CRISPR
Biomaterials Smarten Up With CRISPR
The Wyss Institute for Biologically Inspired Engineering at Harvard University
PR-M08-19-NI-068
Aug 23, 2019
1 / 3
